Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Alpha Cognition Inc ACOG

Healthcare Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


NDAQ:ACOG - Post by User

Alpha Cognition Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Post by waves1on Nov 11, 2021 4:54pm
151 Views
Post# 34116988

$ACOG presenting at Q4 Virtual Summit on November 17th!

$ACOG presenting at Q4 Virtual Summit on November 17th!Alpha Cognition Inc. ($ACOG $ACOG.v $ACOGF) will be presenting at the Q4 Virtual Summit hosted by the Investors Summit Group.

$ACOG is scheduled to present at 10:15 AM ET on November 17th, 2021. 

This is a great opportunity to learn about $ACOG and get updated on their recent developments.
 
Sign up for the event here:
https://us06web.zoom.us/webinar/register/WN_5oxO1tQORQKs2TZDYxM-yw

You can find out more about $ACOG and the event here:
https://www.meetmax.com/sched/event_74761/__preslist_cp.html
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities